Cleared Traditional

K955018 - TRIP NGS & SIGMOID CATHETER PHI SLIDE CALCULATOR (FDA 510(k) Clearance)

Class I Gastroenterology & Urology device.

K955018 · Instrumentarium Corp. · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1996
Decision
89d
Days
Class 1
Risk

K955018 is an FDA 510(k) clearance for the TRIP NGS & SIGMOID CATHETER PHI SLIDE CALCULATOR. Classified as Electrode, Ph, Stomach (product code FFT), Class I - General Controls.

Submitted by Instrumentarium Corp. (Boston, US). The FDA issued a Cleared decision on January 30, 1996 after a review of 89 days - a notably fast clearance cycle.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.1400 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Instrumentarium Corp. devices

Submission Details

510(k) Number K955018 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 02, 1995
Decision Date January 30, 1996
Days to Decision 89 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
41d faster than avg
Panel avg: 130d · This submission: 89d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FFT Electrode, Ph, Stomach
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.1400
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.